We are live on ! Find out more
AVDL

Avadel Pharmaceuticals
AVDL

Delisted

AVDL was delisted on the 11th of February, 2026.

Back to rankings

94 hedge funds and large institutions have $435M invested in Avadel Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 30 increasing their positions, 19 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

278% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 9

58% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 19

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

32% more funds holding

Funds holding: 71 → 94 (+23)

31% more capital invested

Capital invested by funds: $332M → $435M (+$103M)

41% less call options, than puts

Call options by funds: $910K | Put options by funds: $1.53M

Holders
94
Holders Change
+23
Holders Change %
+32.39%
% of All Funds
2.51%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.11%
New
34
Increased
30
Reduced
19
Closed
9
Calls
$910K
Puts
$1.53M
Net Calls
-$625K
Net Calls Change
-$1.47M

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$9.51M
2
CM
Castleark Management
Illinois
+$8.52M
3
Millennium Management
Millennium Management
New York
+$6.58M
4
BFA
BlackRock Fund Advisors
California
+$6.32M
5
MACM
March Altus Capital Management
Connecticut
+$5.64M

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$18.3M
2
CCP
Clough Capital Partners
Massachusetts
-$12.7M
3
PC
PointState Capital
New York
-$5.72M
4
TI
Turner Investments
Pennsylvania
-$3.62M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$3.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
BCM
76
Bourgeon Capital Management
Connecticut
$171K -$303K -21,200 -68%
FAAS
77
First Allied Advisory Services
California
$171K +$143K +10,000 New
Citigroup
78
Citigroup
New York
$136K +$113K +7,920 New
CCM
79
Cupps Capital Management
Illinois
$130K +$109K +7,625 New
Royal Bank of Canada
80
Royal Bank of Canada
Ontario, Canada
$113K +$1.66K +116 +2%
Barclays
81
Barclays
United Kingdom
$102K +$81.9K +5,734 +2,132%
Northern Trust
82
Northern Trust
Illinois
$69K +$28.2K +1,975 +95%
TRCT
83
Tower Research Capital (TRC)
New York
$50K +$40.5K +2,836 +2,836%
GXMC
84
Global X Management Company
New York
$27K +$771 +54 +4%
KFA
85
Kelleher Financial Advisors
New York
$25K +$21.4K +1,500 New
LTFS
86
Ladenburg Thalmann Financial Services
Florida
$19K -$4.21K -295 -21%
Lazard Asset Management
87
Lazard Asset Management
New York
$17K – – –
WA
88
WFG Advisors
Texas
$10K – – –
WC
89
Whitnell & Co
Illinois
$9K – – –
Creative Planning
90
Creative Planning
Kansas
$9K +$7.14K +500 New
Fifth Third Bancorp
91
Fifth Third Bancorp
Ohio
$9K +$7.14K +500 New
BRWM
92
B. Riley Wealth Management
Tennessee
$5K – – –
HMS
93
Hanseatic Management Services
New Mexico
$2K – – –
BRWA
94
B. Riley Wealth Advisors
Florida
$17 +$14.3K +1,000 New
JP Morgan Chase
95
JP Morgan Chase
New York
– -$18.3M -1,275,916 Closed
CCP
96
Clough Capital Partners
Massachusetts
– -$12.7M -887,650 Closed
PC
97
PointState Capital
New York
– -$5.72M -400,000 Closed
BIM
98
Bogle Investment Management
Massachusetts
– -$1.86M -129,736 Closed
Neuberger Berman Group
99
Neuberger Berman Group
New York
– -$905K -63,300 Closed
ICAP
100
Independence Capital Asset Partners
Colorado
– -$780K -54,500 Closed
1 2 3
4
5

AVDL Hedge Fund Activity: Q4 2014 in Review

94 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q4 2014, worth a combined $435M — up 31% from $332M a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new AVDL positions and 9 closed out — a net gain of 25 holders — while 30 added to existing stakes and 19 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $9.51M. The largest seller was JP Morgan Chase, exiting entirely with an estimated $18.3M sold.

  • 94 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q4 2014, up from 71 in Q3 2014.
  • Funds reported $435M of Avadel Pharmaceuticals stock for Q4 2014, up 31% quarter-over-quarter.
  • 34 funds opened new Avadel Pharmaceuticals positions in Q4 2014 and 9 closed out, a net change of +25 holders.
  • The largest Avadel Pharmaceuticals buyer in Q4 2014 was T. Rowe Price Associates, an estimated $9.51M added.
  • The largest Avadel Pharmaceuticals seller in Q4 2014 was JP Morgan Chase, an estimated $18.3M sold.

Based on aggregated 13F filings for Q4 2014.